mRNA Vaccine Co-expressing Zika Virus Envelope EDIII and Non-structural Protein NS1 Achieves 100% Protection Against Lethal Infection
Background
The Zika virus (ZIKV) is a Flaviviridae pathogen transmitted by Aedes mosquitoes. It poses a significant threat, causing fetal microcephaly upon infection in pregnant women and severe neurological complications like Guillain-Barré syndrome in adults. Despite a WHO declaration of a Public Health Emergency of International Concern following the 2015 Latin American epidemic, no approved therapeutics or commercial vaccines exist.
A major hurdle in existing vaccine development is the risk of antibody-dependent enhancement (ADE) inherent to Flaviviruses. Targeting the entire viral envelope (E) protein or its precursor membrane protein often induces large amounts of non-neutralizing antibodies. When these antibodies bind to viruses like Dengue, they facilitate host immune cell entry, thereby exacerbating the infection.
To achieve both safety and efficacy, researchers adopted a precise antigen combination. They focused on envelope domain III (EDIII), which effectively induces neutralizing antibodies while having fewer cross-reactive epitopes. The concept involves combining with non-structural protein 1 (NS1), which is secreted from infected cells and causes vascular damage, to encompass cellular immunity.
Key Findings
Researchers developed lipid nanoparticle (LNP) messenger RNA (mRNA) vaccines expressing EDIII and NS1, respectively, based on the sequence of the Zika virus FSS13025 strain. Physicochemical analysis showed both monovalent vaccines exhibited a polydispersity index (PDI) of less than 0.2, indicating uniform particle size, and a high encapsulation efficiency of over 80%.
In immunogenicity evaluations using mice, both candidates induced high antigen-specific antibodies in a dose-dependent manner. According to the 50% plaque reduction neutralization test (PRNT50), a measure of humoral immunity, the EDIII monovalent vaccine induced an appropriate level of neutralizing antibody titers. Conversely, due to the nature of the non-structural protein not being exposed on the viral surface, no neutralizing antibodies were detected in the NS1 monovalent vaccine.
The distinguishing feature of the combined bivalent vaccine was the powerful activation of cellular immunity. Splenocyte analysis in mice showed that the EDIII + NS1 combined mRNA vaccine significantly increased interferon-gamma (IFN-γ) secretion and promoted a Th1-biased immune response compared to the monovalent vaccines.
In lethal infection animal models, the effect of combination therapy was demonstrated by an overwhelming difference in survival rates. When mice were administered 100,000 plaque-forming units (1×10^5 PFU) of Zika virus isolated from the Chinese Center for Disease Control and Prevention (China CDC) via intraperitoneal injection, the combined vaccine group recorded a 100% survival rate across all tested dose groups. In contrast, groups receiving EDIII or NS1 alone experienced mortality even at a 20 microgram (µg) dose, and the 10µg dose group showed a mortality rate exceeding 50%.
Significance and Outlook
This is evaluated as a case in which the humoral immunity induced by structural proteins and the cellular immunity induced by non-structural proteins acted complementarily to completely bridge the protective gap. It serves as an exemplary model of maximizing preventive efficacy through combination design, overcoming the limitations observed with monovalent administration.
The achievement of perfect survival rates while suppressing ADE side effects is also noteworthy. By removing envelope domains I and II, which cause cross-reactivity with Dengue, and precisely incorporating only EDIII, the risk of cross-infection was minimized. Combined with NS1-mediated cellular immunity that directly attacks infected cells, viral replication was blocked twofold.
Further validation for human clinical trials remains an essential task. Subsequent steps must confirm whether the complete protection achieved in rodent models is maintained in non-human primates and actual patients. Future research must track the long-term durability of neutralizing antibodies and the formation of immune memory in populations with a history of Dengue virus exposure.
BACKGROUND: There is evidence for the protective effects of antibodies targeting non-structural protein 1 (NS1) of Zika virus (ZIKV); however, effective vaccines against ZIKV remain lacking. METHODS: In this study, lipid nanoparticle (LNP)-encapsulated mRNA vaccines were designed based on the envelope domain III (EDIII) and NS1 sequences of the ZIKV FSS13025 strain, while protective efficacy was evaluated in a murine model using a ZIKV isolate obtained from Zhejiang Provincial Center for Disease Control and Prevention (Zhejiang CDC). RESULTS: The vaccines were evaluated for key quality attributes-including particle size, polydispersity index (PDI), and encapsulation efficiency-as well as immunogenicity and protective efficacy. Both monovalent vaccine components exhibited uniform particle sizes (PDI < 0.2) and high encapsulation efficiencies (≥80%) and induced high levels of antigen-specific antibodies in mice in a dose-dependent manner. The EDIII mRNA vaccine elicited moderate ZIKV-neutralizing antibody titers as measured by PRNT CONCLUSIONS: These results demonstrate that the bicomponent EDIII + NS1 mRNA vaccine combination confers superior protective efficacy compared with either component alone, consistent with a synergistic effect between humoral and cellular immune responses. This study provides a novel strategy for next-generation Zika vaccine development.
This study serves as a key milestone in designing next-generation vaccines to safely protect pregnant women and high-risk groups in subtropical regions where dengue and Zika co-circulate. It achieves protection superior to that of a single formulation while avoiding the risk of antibody-dependent enhancement associated with full-length envelope protein vaccines.
From an industrial perspective, it provides an opportunity to maximize the production efficiency of LNP-based multivalent mRNA vaccines. By loading two antigen sequences into a lipid nanoparticle platform without complex protein purification processes, the manufacturing process can be significantly streamlined. As mosquito habitats expand due to climate change, this is expected to serve as a practical development guideline for establishing rapid-response national vaccine stockpiles.